Drug Trial Radar · NCT06057571
Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor
Last checked: Nov 19, 2026Latest source record: Aug 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Nov 17, 2023
Primary completion
Jul 27, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- TransThera Sciences (Nanjing), Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase II, open-label, multicenter study to evaluate the efficacy and safety of oral TT-00420 (Tinengotinib) tablets in subjects with cholangiocarcinoma who failed or relapsed to prior treatment of chemotherapy and FGFR Inhibitor.
Conditions
- Cholangiocarcinoma Metastatic
Interventions
TT-00420 (tinengotinib)Drug
TT-00420 (tinengotinib) tablet will be administered orally once daily per protocol defined schedule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) by BICRTime frame: Through study completion, an average of 1 year
Locations
29 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, China
Beijing Cancer Hospital
Beijing, China
Beijing Tsinghua Changgeng Hospital
Beijing, China
Fudan University Shanghai Cancer Hospital
Shanghai, China
Zhongshan Hospital
Shanghai, China
Tianjin medical university cancer institute & hospital
Tianjin, China
Anhui Provincial Hospital
Hefei, Anhui, China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Shenzhen Qianhai Shekou Free Trade Zone hospital
Shenzhen, Guangdong, China
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Hubei Cancer Hospital
Wuhan, Hubei, China
Zhongnan hospital of Wuhan University
Wuhan, Hubei, China
Hunan Cancer Hospital
Changsha, Hunan, China
Hunan Provincial People's Hospital
Changsha, Hunan, China
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
Jilin Cancer Hospital
Changchun, Jilin, China
Liaoning Cancer Hospital
Shenyang, Liaoning, China
Central Hospital Affiliated to Shangdong First Medical University
Jinan, Shandong, China
Shandong Cancer Hospital
Jinan, Shandong, China
Eastern Hepatobiliary Surgery Hospital
Shanghai, Shanghai Municipality, China
Shanxi Cancer Hospital
Taiyuan, Shanxi, China
Sichuan Cancer Hospital
Chengdu, Sichuan, China
Yunnan Cancer Hospital
Kunming, Yunnan, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.